$XPL

Solitario (XPL) Advances 2026 Ponderosa Drilling Program

Solitario Resources (NYSEAMERICAN:XPL) said its 2026 Ponderosa drilling program is well advanced at its 100%-owned Golden Crest gold project in South Dakota. Four core holes are completed, samples are being shipped, and initial assay results are expected in early August. The company is also preparing for first drilling at its Cat Creek critical metals project and advancing permits for Bright Angel.

Original reporting
Published Jul 10, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$XPL
Neutral
medium confidence
Mentioned
$XPL
Relevance
4/10
alphai data visualization · based on yahoo.com
Decision brief

The 30-second read

$XPLNeutralLow
01

Why it matters

The most tradable element is the early-August assay expectation for Ponderosa, which can drive volatility in a micro/small-cap explorer. Cat Creek and Bright Angel add longer-dated optionality but lack concrete near-term milestones in the text.

02

Market read

Operational update with a defined assay window, but no assay results or financial guidance changes.

03

What to watch

Cat Creek is described as first-ever drilling and Bright Angel permit advancement, but the article provides no timelines, permitting status, or budget details that would affect near-term valuation.

Relevance 4/10Novelty 4/10Timing: assay results expected in early August, after four Ponderosa core holes completed

Background

Solitario is advancing multiple 100%-owned US projects, with Ponderosa drilling underway and Cat Creek and Bright Angel in preparation/permit stages.

Company-level read

Ticker impact

$XPLNeutralMedium confidence
Context

Solitario says its 2026 Ponderosa drilling is well advanced with four core holes completed and initial assays due in early August.

Expected impact

Likely modest upside bias into early-August assay results if assays confirm resource potential; otherwise limited follow-through.

Evidence & confidence

The article provides specific operational milestones (holes completed, samples shipped/prep) and a concrete expected assay window, but no assay numbers or guidance changes.

Market effects

Adds incremental newsflow for US-based gold exploration names, but without assay results it is unlikely to move the broader silver/gold penny-stock complex.

Limited regional impact, focused on South Dakota and Colorado drilling activity.

Low global relevance; no commodity price, policy, or major project-scale disclosure beyond drilling progress.

Counterpoint

Drilling progress can be largely routine; without assay grades or intercepts, the market may discount the update until results arrive.

Key entities

  • Solitario Resources Corp.

    Announced progress on its 2026 Ponderosa drilling program and preparations for Cat Creek drilling, with initial assays expected in early August.

Related articles

$PSXMed

Good news for San Diego drivers? A $5B fuel pipeline project advances

Phillips 66, Kinder Morgan and HF Sinclair said they made a final investment decision to proceed with the $5 billion Western Gateway Pipeline, aiming for completion in 2029 subject to permits. The 1,300-mile system would move refined fuels into the West with 230,000 bpd capacity and potential Southern California gasoline price relief. Ownership: Phillips 66 49.9%, Kinder Morgan 35.1%, HF Sinclair 15%.

Med

Glenmark’s U.S. unit settles Humana antitrust case for $15.3 mln

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.

$PLTRMed

Give Palantir up to $244m through 2028, says internal Defense Department memo

An internal US Defense Department memo reportedly directs subordinates to buy up to $243.9 million in services from Palantir through March 31, 2027, without competitive bidding, and to identify additional funding for April 1, 2027 to Dec. 31, 2028. The memo cites Palantir support for defense industrial base efficiency and munitions/vehicle delays. Palantir is a public company.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.